August 20, 2014 10:06 PM ET

Pharmaceuticals

Company Overview of Cardioxyl Pharmaceuticals, Inc.

Company Overview

Cardioxyl Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes nitroxyl therapies for the treatment of cardiovascular disease. The company’s program is focused on the development of proprietary nitroxyl donors for the treatment of acute decompensated heart failure (ADHF). Its programs target chronic heart failure and pulmonary arterial hypertension, as well as other cardiovascular therapeutic indications. The company conducts clinical trial of CXL-1427, a nitroxyl prodrug for clinical development as a treatment for ADHF. Cardioxyl Pharmaceuticals, Inc. was founded in 2005 and is based in Chapel Hill, North Carolina.

1450 Raleigh Road

Exchange East

Suite 212

Chapel Hill, NC 27517-8833

United States

Founded in 2005

Phone:

919-869-8585

Fax:

410-339-7847

Key Executives for Cardioxyl Pharmaceuticals, Inc.

Chief Executive Officer
Scientific Co-Founder and Member of Scientific Advisory Board
Scientific Co-Founder
Scientific Co-Founder and Member of Scientific Advisory Board
Founder and Senior Vice President of Chemistry & Pre-Clinical Development
Compensation as of Fiscal Year 2014.

Cardioxyl Pharmaceuticals, Inc. Key Developments

Cardioxyl Pharmaceuticals, Inc. Announces Positive Results of Clinical Trial Demonstrating for Heart Failure Drug CXL-1427

Cardioxyl Pharmaceuticals, Inc. announced the positive results of a clinical trial demonstrating that CXL-1427, a novel potential treatment for acute decompensated heart failure (ADHF), was well tolerated in healthy volunteers. The company has now initiated dosing of hospitalized patients with decompensated heart failure in a Phase IIa clinical trial designed to further evaluate the drug's safety and tolerability as well as its dosing levels. The Phase I clinical trial evaluated the safety and tolerability of 24- and 48-hour continuous intravenous infusions of CXL-1427 in 80 healthy volunteers. The trial's results showed not only that CXL-1427 was well tolerated with limited adverse events, but also that it is clearly hemodynamically active. Cardioxyl's ongoing Phase IIa study is a randomized, double-blinded, placebo-controlled, invasive hemodynamic study designed to evaluate the safety, tolerability and hemodynamic effects of 6-hour intravenous infusions of CXL-1427 in hospitalized patients with advanced heart failure. It is being conducted at up to 34 clinical sites globally and will enroll approximately 48 hospitalized patients. Nitroxyl, the chemical name for HNO, has been studied for it's potential as a treatment for heart failure. HNO dilates blood vessels and acts directly on the heart through a unique mechanism to safely enhance both systolic and diastolic function. Cardioxyl's proprietary platform of HNO technology has produced a number of candidate therapeutics for treating heart failure, including CXL-1427.

Cardioxyl Pharmaceuticals, Inc. Initiates First Clinical Trial of CXL-1427

Cardioxyl Pharmaceuticals, Inc. announced that the first cohort of patients has been dosed in a Phase I clinical trial of CXL-1427, a novel nitroxyl (HNO) prodrug optimized for clinical development as a potential treatment for acute decompensated heart failure (ADHF). The primary objective of the Phase 1 clinical trial is to evaluate the safety and tolerability of continuous intravenous infusions of CXL-1427 for up to 48-hours in healthy volunteers. This Phase I trial of CXL-1427, which is set to be conducted over the first half of 2014, is a randomized, double-blind, placebo-controlled ascending dose evaluation of CXL-1427 in healthy volunteers. The study will enroll up to a total of 110 subjects and will evaluate the safety and pharmacokinetics of 24- and 48-hour infusions of CXL-1427. Pending successful completion of this Phase 1 trial, Cardioxyl anticipates initiating subsequent trials of CXL-1427 in patients with acute decompensated heart failure.

Cardioxyl Pharmaceuticals, Inc. Appoints Shi Yin Foo as Chief Medical Officer

Cardioxyl Pharmaceuticals, Inc. announced the appointment of Shi Yin Foo, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Foo, who has broad experience in the development of cardiovascular drugs and translational medicine, is well positioned to help Cardioxyl realize the potential of its nitroxyl (HNO) technology for the treatment of patients with serious cardiovascular disease. Dr. Foo joins Cardioxyl from Novartis, where she was responsible for the establishment and execution of multiple novel programs in heart failure and the cardiorenal space, and is a named inventor on several associated patents applications.

Similar Private Companies By Industry

Company Name Region
CEPTYR, Inc. United States
Drais Pharmaceuticals, Inc. United States
Antegrin Therapeutics LLC United States
Hapten Sciences, Inc. United States
Voyager Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cardioxyl Pharmaceuticals, Inc., please visit www.cardioxyl.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.